Spyre Therapeutics Inc. (SYRE), which made significant advancements in its next-generation inflammatory bowel disease pipeline in 2024, has two clinical trial data releases planned for this year.
The company's lead drug candidate is SPY001, a novel, subcutaneous extended half-life monoclonal antibody targeting a4ß7 for the potential treatment of inflammatory bowel disease. Integrin a4ß7 plays a crucial role in the pathogenesis of inflammatory bowel disease.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.